Governors Lane LP Grows Stock Position in Drugs Made In America Acquisition Corp. $DMAA

Governors Lane LP boosted its stake in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 2,132.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 250,000 shares of the company’s stock after buying an additional 238,800 shares during the period. Governors Lane LP owned approximately 0.86% of Drugs Made In America Acquisition worth $2,594,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Wolverine Asset Management LLC raised its holdings in Drugs Made In America Acquisition by 4.7% during the 4th quarter. Wolverine Asset Management LLC now owns 1,307,468 shares of the company’s stock valued at $13,564,000 after buying an additional 58,340 shares during the period. Mercuria Capital Strategies LLC purchased a new stake in Drugs Made In America Acquisition during the 4th quarter valued at $7,511,000. Boothbay Fund Management LLC purchased a new stake in Drugs Made In America Acquisition during the 2nd quarter valued at $5,814,000. Radcliffe Capital Management L.P. raised its holdings in Drugs Made In America Acquisition by 3.5% during the 4th quarter. Radcliffe Capital Management L.P. now owns 546,808 shares of the company’s stock valued at $5,673,000 after buying an additional 18,708 shares during the period. Finally, Clear Street Group Inc. increased its stake in Drugs Made In America Acquisition by 55.5% in the fourth quarter. Clear Street Group Inc. now owns 325,973 shares of the company’s stock worth $3,382,000 after purchasing an additional 116,407 shares during the period.

Drugs Made In America Acquisition Price Performance

Shares of DMAA opened at $10.62 on Thursday. Drugs Made In America Acquisition Corp. has a 12-month low of $10.17 and a 12-month high of $10.63. The firm has a fifty day moving average price of $10.58 and a 200-day moving average price of $10.48.

Drugs Made In America Acquisition (NASDAQ:DMAA) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.06 earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank?check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.